内脏静脉血栓形成的抗凝治疗:个体患者数据荟萃分析
本研究通过个体患者数据荟萃分析评估抗凝治疗对内脏静脉血栓形成(SVT)的有效性和安全性,纳入3项研究共1635例患者,其中85%接受抗凝治疗,中位疗程316天。抗凝治疗与复发性静脉血栓栓塞、大出血和死亡率风险降低相关。
要点
- 抗凝治疗与复发性VTE风险降低相关(HR 0.42)。
- 抗凝治疗与大出血风险降低相关(HR 0.47)。
- 抗凝治疗与死亡率风险降低相关(HR 0.23)。
核心结论
- 在内脏静脉血栓形成患者中,复发性静脉血栓栓塞和大出血风险均较高,抗凝治疗与这两种结局风险降低相关。
研究设计与样本
- 个体患者数据荟萃分析,检索Medline、Embase和clinicaltrials.gov至2021年6月,纳入前瞻性队列或随机临床试验,共3项研究1635例SVT患者。
主要发现
- 85%患者接受抗凝治疗,中位疗程316天(范围1-730天)。
- 复发性VTE发生率为5.3/100患者年(95%CI 5.1-5.5),大出血为4.4/100患者年(95%CI 4.2-4.6),死亡率为13.0/100患者年(95%CI 12.4-13.6)。
- 抗凝治疗期间所有结局发生率较低,停药后或未抗凝时较高。
- 多变量分析显示,抗凝治疗似乎与复发性VTE风险降低相关(HR 0.42;95%CI 0.27-0.64)。
- 多变量分析显示,抗凝治疗似乎与大出血风险降低相关(HR 0.47;95%CI 0.30-0.74)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Robust evidence on the optimal management of splanchnic vein thrombosis (SVT) is lacking. We conducted an individual-patient meta-analysis to evaluate the effectiveness and safety of anticoagulation for SVT. Medline, Embase, and clincaltrials.gov were searched up to June 2021 for prospective cohorts or randomized clinical trials including patients with SVT. Data from individual datasets were merged, and any discrepancy with published data was resolved by contacting study authors. Three studies of a total of 1635 patients were included. Eighty-five percent of patients received anticoagulation for a median duration of 316 days (range, 1-730 days). Overall, incidence rates for recurrent venous thromboembolism (VTE), major bleeding, and mortality were 5.3 per 100 patient-years (p-y; 95% confidence interval [CI], 5.1-5.5), 4.4 per 100 p-y (95% CI, 4.2-4.6), and 13.0 per 100 p-y (95% CI, 12.4-13.6), respectively. The incidence rates of all outcomes were lower during anticoagulation and higher after treatment discontinuation or when anticoagulation was not administered. In multivariable analysis, anticoagulant treatment appeared to be associated with a lower risk of recurrent VTE (hazard ratio [HR], 0.42; 95% CI, 0.27-0.64), major bleeding (HR, 0.47; 95% CI, 0.30-0.74), and mortality (HR, 0.23; 95% CI, 0.17-0.31). Results were consistent in patients with cirrhosis, solid cancers, myeloproliferative neoplasms, unprovoked SVT, and SVT associated with transient or persistent nonmalignant risk factors. In patients with SVT, the risk of recurrent VTE and major bleeding is substantial. Anticoagulant treatment is associated with reduced risk of both outcomes.
引用
- Candeloro M, Valeriani E, Monreal M, et al. Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Adv. 2022. PMID: 35613465. doi:10.1182/bloodadvances.2022007961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。